Vanda Pharmaceuticals (NASDAQ:VNDA) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $20.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com initiated coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a “hold” rating for the company.

Vanda Pharmaceuticals Price Performance

NASDAQ VNDA opened at $4.50 on Tuesday. The firm has a market capitalization of $262.42 million, a price-to-earnings ratio of -14.06 and a beta of 0.69. The company has a 50 day simple moving average of $4.67 and a 200-day simple moving average of $4.74. Vanda Pharmaceuticals has a 52-week low of $3.87 and a 52-week high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.06. The firm had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. On average, analysts predict that Vanda Pharmaceuticals will post -1.12 EPS for the current year.

Insider Buying and Selling at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the stock in a transaction on Wednesday, March 5th. The shares were purchased at an average cost of $5.02 per share, with a total value of $50,200.00. Following the completion of the transaction, the chief executive officer now directly owns 2,285,731 shares of the company’s stock, valued at $11,474,369.62. This represents a 0.44 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders acquired 32,000 shares of company stock worth $151,180 over the last ninety days. 8.90% of the stock is currently owned by insiders.

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Intech Investment Management LLC bought a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at approximately $84,000. Charles Schwab Investment Management Inc. grew its holdings in Vanda Pharmaceuticals by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock valued at $2,796,000 after purchasing an additional 3,473 shares during the last quarter. FMR LLC raised its position in shares of Vanda Pharmaceuticals by 25.9% in the third quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock valued at $702,000 after purchasing an additional 30,802 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Vanda Pharmaceuticals by 1,184.6% in the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 57,393 shares during the last quarter. Finally, Verition Fund Management LLC boosted its holdings in shares of Vanda Pharmaceuticals by 7.8% during the 3rd quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 2,927 shares during the period. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.